Treatment of adult and pediatric high-grade gliomas with Withaferin A: antitumor mechanisms and future perspectives

J Nat Med. 2017 Jan;71(1):16-26. doi: 10.1007/s11418-016-1020-2. Epub 2016 Jul 2.

Abstract

Resistance mechanisms employed by high-grade gliomas allow them to successfully evade current standard treatment of chemotherapy and radiation treatment. Withaferin A (WA), utilized in Ayurvedic medicine for centuries, is attracting attention for its antitumor capabilities. Here we review pertinent literature on WA as a high-grade glioma treatment, and discuss the cancerous mechanisms it affects. WA is relatively nontoxic and has shown potential in crossing the blood-brain barrier. WA prevents p53 alterations and inactivates overexpressed MDM2 through ARF and ROS production. Furthermore, WA upregulates Bax, inducing mitochondrial death cascades, inhibits mutated Akt, mTOR, and NF-κB pathways, and inhibits angiogenesis in tumors. Therapy with WA for high-grade gliomas is supported through the literature. Further investigation is warranted and encouraged to fully unearth its abilities against malignant gliomas.

Keywords: Astrocytoma; Brain cancer; Chemotherapy; Experimental therapy; Glioblastoma; High-grade glioma; Mechanisms of action; Withaferin A.

Publication types

  • Review

MeSH terms

  • Adult
  • Brain Neoplasms / drug therapy*
  • Brain Neoplasms / pathology
  • Glioma / drug therapy*
  • Glioma / pathology
  • Humans
  • Withanolides / administration & dosage
  • Withanolides / therapeutic use*

Substances

  • Withanolides
  • withaferin A